3G0

Altimmune Inc

Healthcare · EUR · F

3G0

Price

€2.473

+2.27%

Cap

€600.56M

Earnings

30d Trend

-15.0%

3G0
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityHigh

45% annualised over 90 days

BRAIN47 SIGNAL

0
MODERATE
Risk Level74
Quality15
Momentum50
Technical47
Fundamentals55

Raw weighted: 40×Macro 0.99 (1%)=40

RISK

74/100
90d Volatility
45.2%High
ATR %
6.5%High daily moves
Max Drawdown (1Y)
-33.9%Volatile

QUALITY

15/100
Piotroski F-Score
2/9Weak
Margin Stability
CV 51.3%Volatile

MOMENTUM

50/100
12-1M Momentum
+4.0%Uptrend
6-1M Momentum
-1.9%Flat
1M Return
-15.9%Sharp decline

TECHNICAL

47/100
RSI (14)
30.4Neutral
Price vs SMA200
-17.5%Bearish trend
MACD
+0.07Bullish momentum
Bollinger Band
33%Mid-range
SMA Cross
Golden CrossGolden Cross
Trend Quality (KER)
0.636Clean trend

FUNDAMENTALS

55/100
EV/EBIT
28.4Expensive
P/S
0.4Cheap
PEG
0.12Growth at discount
Shareholder Yield
0.0%Low

Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months54
3-12 months29
1-5+ years32

Limited short-term thesis

BRAIN47'S ASSESSMENT

I rate Altimmune Inc at 40/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is fundamentals at 55/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.

PAST PERFORMANCE

1 MONTH

-15.9%

3 MONTHS

-17.8%

12 MONTHS

-11.9%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

Limited short-term thesis. Fundamentals (55) and Momentum (50) are the primary strengths. I note that quality is the weakest area at 15/100 — this warrants monitoring. Historical volatility is elevated at 45%. I classify this as a speculative position — elevated volatility at 45% and smaller market cap define the opportunity.

speculativeScore: 40/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.